

Beyond Inspiration and Invention: to Innovation: Translational Science at NIH



Rosemarie Hunziker

Program Director, Tissue Engineering and Regenerative Medicine
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
National Institutes of Health (NIH)

301-451-1609

Rosemarie.Hunziker@nih.gov



Largest Impact?




Paul Lauterbur and Peter Mansfield

Magnetic
Resonance
Imaging



Raymond Damadian



Paul Berg, Walter Gilbert, and Fred Sanger

Recombinant
DNA



Herb Boyer and Bob Swanson

Between Invention and Innovation:

Moving Technology from the Laboratory to the Marketplace

Branscumb and Auerswald (2002). NIST GCR 02-841

Crossing

The Valley of Death



Death Valley suggests a barren territory. In reality, between the stable shores of the science and technology environment and the business and finance enterprise is a sea of business and technical ideas, of big fish and little fish contending, with survival going to the creative, the agile, the persistent.

Translational Medicine:

moving the development of new drugs, devices, and treatment options from bench to bedside; translating research into practice



You are here



The Broad Reach of the NIH



There are resources--
**FY11 budget:
\$31B**

NIH *is* an institution
(Intramural Research)

- ~ 6,000 scientists
- ~ 10% of NIH budget

NIH *supports* institutions & people
(Extramural Research)

- > 4,000 institutions
- > 300,000 scientists & research personnel
- ~ 85% of the NIH budget

NIH Grant Statistics

Fiscal Year 2010

- **62,000** applications reviewed
- **240** Review Officers organized **1,600** meetings with **18,000** reviewers
- **16,600+** new grants awarded

We have lots of experience in evaluating science!



... improving health by leading the development and accelerating the application of biomedical technologies




NIH is organized into:



Institutes & Centers (IC) each
represent:
The culture is complex.

- budget
- ways of deciding grants to fund

“Family Tree” for Grants



There are many, many mechanisms available!

Other Funding

R01
(standard grant)

P20, P34
(planning grant)

R01
(standard grant)

P30, P40, P41, P42, P43, P44

R03
(small grant)

R01
(standard grant)

R21
(exploratory/developmental)

R03
(small grant)

R01
(Biological Research Partnership)

R21
(exploratory/developmental)

R41, R43
(feasibility)

R42, R44
(development)


Sorting out the locus for Translational Research...



Some examples of translational research supported by NIH...


Find a Trusted Guide!

Small Business Innovation Research (SBIR) Small Business Technology Transfer (STTR) Programs



PHASE I – Feasibility Study

- Average award: \$170K
- Project period varies, most 6 – 12 months



PHASE II – Full R&D

- Average \$850K, 2 years but some longer
- Commercialization plan required






PHASE III – Commercialization

- Use of non-SBIR/STTR Funds
- Consider exit strategy

Issues

- Budgets inadequate for expectations
- Gap between Phases I and II can be almost two years
- Reviewers do not understand challenges of the “D” in “R&D”

NIH SBIR Gap Funding Programs



- Phase II
Competing
Renewal Award

Phase I → Phase II → Phase III

- No-Cost Extension
- Phase I / Phase II Fast Track
- Administrative / Competitive Supplements



NIH Phase I/Phase II Fast-Track


Critical Considerations



**Are you ready
to run with the
big dogs?**

- Review both Phases together
- Convincing preliminary data
- Clear, measurable, achievable milestones, especially for the Phase II transition after administrative review
- Well-conceived, compelling Commercialization Plan
- Letters of Phase III support/interest?
- Track record for commercializing?
- Discussed with NIH Program Staff?

SBIR Phase II + Competing Renewal Awards



- Take existing, promising compounds or devices developed in Phase II through the next step of drug discovery/medical device refinement and development
- Support complex instrumentation, clinical research tools, behavior interventions
- Not all ICs participate

CTSA Clinical & Translational Science Awards[®]

Translating Discoveries to Medical Practice


<http://ctsaweb.org/>

Goals:


- create a definable academic home for clinical and translational research
- transform the local, regional, and national environment for clinical research and training

Features:

- Integrates diverse teams from across academia, university hospitals, industry
- 60 institutions in 30 states and DC
- Collaborations encouraged



Cross-Cutting, trans-NIH Programs



<http://commonfund.nih.gov/>



Ongoing Investments in Innovation



The NIH Common Fund invests millions of dollars to fund new high-risk research to explore ideas that have strong potential to improve health



Transformative R01 Program places the emphasis on creative ideas—projects with the potential to overturn paradigms. Flexible budgets. (79 awards since 2009).



Pioneer Awards support individual scientists of exceptional creativity who propose pioneering approaches to major challenges in biomedical and behavioral research (94 awards since 2004).



New Innovator Program address two important goals: stimulating highly innovative research and supporting promising new investigators (164 awards since 2007).

<http://nihroadmap.nih.gov/>



... improving health by leading the development and accelerating the application of biomedical technologies



NIH's Role in Comparative Effectiveness Research (CER)





Key NIH CER Activities

- **Research** to generate evidence enabling physicians and patients to optimize health care decisions.
- Research **training** to develop the CER workforce.
- **Personalized Medicine** probes impact of uniqueness of individuals and special populations.
- CER **Centers** support integration and dissemination of evidentiary knowledge.
- **Behavioral Economics** to increase “uptake” of CER findings by providers and payers.

Key Considerations

- Emerging Role of NIH in CER: differentiating from AHRQ?
- Early standards efforts can accelerate effective translation.

More at: <http://www.nejm.org/doi/full/10.1056/NEJMp1109407>



NIH and Non-Hypothesis Driven Research

There are two kinds of scientific revolutions, those driven by new tools and those driven by new concepts... The effect of a concept-driven revolution is to explain old things in new ways. The effect of a tool-driven revolution is to discover new things that have to be explained.

-Freeman Dyson, 1997



... improving health by leading the development and accelerating the application of biomedical technologies



Getting Funded in an Emerging Field

NIH funds **high risk/high reward** research if there is

- Potential for high impact
- Novel approach, not necessarily a new idea (a fundamental publication builds credibility)
- Deep expertise in the general area on the team (confidence in capability is key)
- A compelling research plan—anticipate obstacles and propose alternatives
- **BONUS POINTS:** reviewer familiarity with the basics



... improving health by leading the development and accelerating the application of biomedical technologies





NIH Public-Private Partnership Program

Improving the Nation's health by facilitating collaborations between the NIH and other public and private partners

Value Proposition for Stakeholders

- ✓ **For regulators:** enabling science to underpin regulatory decision-making
- ✓ **For industry:** expanding discovery for new targets and applications
- ✓ **For academics:** increasing access to resources for training, higher risk research
- ✓ **For patients:** gaining earlier access to products and services to improve health

■ PPPs represent another public face for the NIH. How NIH is seen, our protection of the public interest, and our protection of NIH in the

http://ppp.od.nih.gov/

Local intranet

100%



<http://ppp.od.nih.gov/pppinfo/description.asp>

Public-Private Partnership Program



Examples



accelerate identification, development and regulatory qualification of biomarkers for: cancer, inflammation and immunity, metabolic disorders, and neuroscience

Alzheimer's Disease Neuroimaging Initiative
- NIA, NIBIB, FDA -



Federal partners: NIAMS, NIA, NIDCR, ORWH, NCCAM, NIMHD
Private partners: Merck, Novartis, Pfizer

Publically available database of gene-gene association studies
-NIH, Pfizer, Affymetrix, Abbott -



welcome trust



BILL & MELINDA GATES foundation


CIHR IRSC
Canadian Institutes of Health Research
Instituts de recherche en sante du Canada

Grand Challenges
in **Global Health**



- effective, inexpensive, simple health tools for low resource settings

Accelerating Drug Development





Bridging Interventional Development Gaps

- Access to contract resources for formulation and GMP Manufacturing
- Assay Development for ADMET, PK/PD
- Drugs (small molecules, biologics) and delivery systems (no vaccines, devices or diagnostics)
- Product Development and Regulatory Advice

(BrIDGs)

- formerly RAID



Therapeutics for Rare and Neglected Diseases

- New chemical entities and repurposed drugs
- Access broad scientific, translational, clinical expertise
- In-kind and collaborative research to accelerate development
- Spans spectrum from lead optimization to IND filing
- Integrated approach: underlying mechanisms thru technology platform development

(TRND)



Production Assistance for Cellular Therapies **National Heart Lung and Blood Program**



- Manufacture a clinical grade product for PIs lacking cGMP facility
- Work closely with FDA to facilitate translation to clinical studies
- Processing Centers
 - Baylor College of Medicine Center for Cell and Gene Therapy
 - Center for Human Cell Therapy, Boston
 - City of Hope Center for Applied Technology Development
 - University of Minnesota Molecular and Cellular Therapeutics Facility
 - University of Wisconsin – Madison, Waisman Biomanufacturing
- Application and Information at:
<http://www.pactgroup.net/>

NIH-FDA Regulatory Science Initiative

- a Common Fund Program

- development and use of the scientific knowledge, tools, standards, and approaches necessary for the assessment of medical product safety, efficacy, quality, potency, and performance



- **ACCELERATING DRUG AND DEVICE EVALUTATION THROUGH INNOVATIVE CLINICAL TRIAL DESIGN** (University of Michigan: William Barsan, Roger Lewis, Donald Berry)
- **REPLACEMENT OCCULAR BATTERY (ROBATT)** (MB Research Labs: Daniel Cevern, George DeGeorge)
- **CHARACTERIZATION/BIOINFORMATICS-MODELING OF NANOPARTICLE:COMPLEMENT INTERACTIONS** (University of Washington: Dennis Hourcade)
- **HEART-LUNG MICROMACHINE FOR SAFETY AND EFFICACY TESTING** (Harvard University: Donald Ingber)


A black and red steam locomotive, the Hogwarts Express, is shown on a track. The front of the train features a large circular headlight with the number '5912' and a sign above it that reads 'HOGWARTS EXPRESS'. The train is moving towards the viewer, and the background shows a blurred landscape with a castle in the distance.

Coming soon: Regulatory Science, Part 2

Microphysiological
Systems
DARPA-BAA-11-73


Integrated
Microphysiological
Systems
RFA-XX-12-XXX

Don't get left behind!



Common Themes in NIH's Translational Research

- **Outcomes/Milestone-driven**
- **Leveraging diverse resources** (often both NIH intramural and extramural collaborations)
- **Multi- and Interdisciplinary investigators**
- **Active FDA involvement**
- **Emphasis on training**
- **Trans-NIH in scope**
- **Early stage/pilot programs (evaluations?)**



National Center for Advancing Translational Science (NCATS)

Proposed Mission:

catalyze the generation of innovative methods and technologies that will enhance the development, testing, and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions

Possible Activities

- Catalyze translation by promoting innovative research that is too risky or too early for commercial investment
- Galvanize and support partnerships: leveraging funds and providing access to tools, technologies, and platforms
- Augment Regulatory Science, especially in conjunction with FDA
- Expand the pre-competitive space with open-access data repositories, and a special focus on promising compounds/devices that failed
- Harness the power of the CTSA program
- Transform through training across boundaries, both scientific and situational
- Streamline administrative processes

See Advisory Committee report at

<http://www.nih.gov/about/director/ncats/acd-report.pdf>

NCATS

Complement—not compete with—
private sector by

- ✓ studying the steps in diagnostics and therapeutics development, testing, and implementation into patient care
- ✓ identifying bottlenecks amenable to re-engineering
- ✓ experimenting with innovative methods to streamline the process



CAN – Cures Acceleration Network (not appropriated)
CTSA – Clinical and Translational Science Awards
ORD – Office of Rare and Neglected Diseases
TRND – Therapeutics for Rare and Neglected Diseases
RAID – Rapid Access to Interventional Development
SBIR – Small Business Innovation Research
STTR – Small Business Technology Transfer Research

“Failure is not an option.”

- Gene Kranz

